Company profile
Mestag Therapeutics Signaling a new era in immunotherapy
Driving fibroblast-immune conversations in cancer and inflammatory diseases.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
SH01 | Transaction MzUyNDY1ODk3M2FkaXF6a2N4
Published 01 Jun 2026 11:52
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ1NjE3ODEyNWFkaXF6a2N4
Published 24 Feb 2025 04:33
AA | Transaction MzQ0MDY0NjI5MmFkaXF6a2N4 | Paper/PDF filed
Published 24 Oct 2024 06:59
PSC02 | Transaction MzQ0MDcyMTkwN2FkaXF6a2N4
Published 23 Oct 2024 08:39
PSC09 | Transaction MzQ0MDcyMTU4NGFkaXF6a2N4
Published 23 Oct 2024 08:32
SH01 | Transaction MzQzOTkxMTY4NWFkaXF6a2N4
Published 17 Oct 2024 05:41
Company registered at Companies House
Mestag Therapeutics was founded in 2020 by leading scientists, drug developers and investors to pioneer new medicines for people affected by inflammatory disease and cancer. Our approach builds on recent data which points to resident cells called fibroblasts as playing a key role in driving disease. Mestag's mission is to lead this emerging field in developing impactful precision medicines for patients through our understanding of activated fibroblast populations and their influence on immune effector cells. Our company was created by global thought-leaders in fibroblast biology, is supported by experienced international investors and is powered by our team of scientists based in Cambridge, UK.
None at present
1 Aug 2024 to 31 Jul 2025
Mestag Therapeutics is a biotechnology company harnessing new insights into fibroblast-immune cell interactions to develop impactful treatments for patients. The company develops sophisticated first-in-class antibodies to improve the lives of people with cancer and inflammatory disease. Cancer continues to be a major public health challenge with around 20...
